Neal Winzelberg, MD
Gastroenterology · Brick, NJNPI 1689764466
Payments from drug & device makers
Across 592 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Janssen Scientific Affairs, LLC$715
- Gilead$693
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$569
- Pfizer$511
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$200%
- Grants$200%
- Food & beverage$9,21097%
- Education$2573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 193 | $2,764 |
| Johnson & Johnson | 106 | $1,858 |
| Janssen Scientific Affairs, LLC | 6 | $715 |
| Gilead | 52 | $693 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 45 | $569 |
| Pfizer | 37 | $511 |
| Bristol Myers Squibb | 44 | $496 |
| E.r. Squibb & Sons, L.L.C. | 3 | $329 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $308 |
| Phathom Pharmaceuticals, Inc. | 12 | $167 |
| Lilly USA, LLC | 11 | $166 |
| Ironwood Pharmaceuticals, Inc | 8 | $114 |
| Romark Laboratories, LC | 7 | $98 |
| Ardelyx, Inc. | 5 | $78 |
| QOL Medical, LLC | 5 | $59 |
| Nestle Healthcare Nutrition Inc. | 4 | $55 |
| Sanofi | 3 | $54 |
| Alfasigma USA, Inc. | 4 | $54 |
| Madrigal Pharmaceuticals | 3 | $53 |
| Braintree Laboratories, Inc. | 3 | $45 |
| Redhill Biopharma Inc. | 3 | $41 |
| Ferring Pharmaceuticals Inc. | 3 | $40 |
| Daiichi Sankyo Inc. | 3 | $39 |
| Amgen | 1 | $32 |
| Intercept Pharmaceuticals, Inc. | 2 | $28 |
| Intra-sana Laboratories | 1 | $27 |
| Shionogi Inc | 1 | $22 |
| Boston Scientific | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Celltrion USA Inc. | 1 | $15 |
| Vivus LLC | 1 | $13 |
| Merck | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,507 in reported general payments places this provider in the 80th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 20 | $770,393 |
| Alosetron Hcl | 81 | $50,817 |
| LinzessLinaclotide | 68 | $40,817 |
| MounjaroTirzepatide | 27 | $27,682 |
| ViberziEluxadoline | 31 | $27,486 |
| Mesalamine | 31 | $22,035 |
| Pantoprazole Sodium | 650 | $18,078 |
| Dexlansoprazole DrDexlansoprazole | 26 | $14,603 |
| Esomeprazole Magnesium | 180 | $9,511 |
| MotegrityPrucalopride Succinate | 17 | $8,991 |
| TrulancePlecanatide | 13 | $7,452 |
| Dicyclomine Hcl | 340 | $6,689 |
| Omeprazole | 367 | $5,605 |
| Colesevelam Hcl | 57 | $4,281 |
| Famotidine | 200 | $4,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,858 | $770,39320 claims |
| AbbVieLinzess, Viberzi | $2,764 | $68,30499 claims |
| Lilly USA, LLCMounjaro | $166 | $27,68227 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $308 | $8,99117 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $569 | $7,45213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Brick
- William BasriBrick$284K
- Mark CereficeBrick$25K
- Arkady BroderBrick$21K
- Kiran RaoSparta$1.3M
- Adekunle AdeotiIrvington$1.2M
- Carl WallachMorristown$766K
- Vinod RustgiNew Brunswick$697K
- Arvind TrindadeNew Brunswick$652K
- Barry KaufmanEgg Harbor Township$595K
- Promila BanerjeeStratford$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.